Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections

View ORCID ProfileAnne Russ, View ORCID ProfileYasmeen Nkrumah-Elie, View ORCID ProfileFrehiwet Hailu, View ORCID ProfileJun Kwon, Tracy Allen, View ORCID ProfileAndrew Shao, Halland Chen
doi: https://doi.org/10.64898/2026.10.13.26365470
Anne Russ
1Impact Health Medical FL PA, Orlando, Florida, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne Russ
Yasmeen Nkrumah-Elie
2ChromaDex, Inc., a Niagen Bioscience Company, Los Angeles, California, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yasmeen Nkrumah-Elie
Frehiwet Hailu
2ChromaDex, Inc., a Niagen Bioscience Company, Los Angeles, California, USA
DVM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frehiwet Hailu
Jun Kwon
2ChromaDex, Inc., a Niagen Bioscience Company, Los Angeles, California, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jun Kwon
  • For correspondence: research{at}niagenbio.com
Tracy Allen
1Impact Health Medical FL PA, Orlando, Florida, USA
MS, NRP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Shao
2ChromaDex, Inc., a Niagen Bioscience Company, Los Angeles, California, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Shao
Halland Chen
1Impact Health Medical FL PA, Orlando, Florida, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Nicotinamide riboside (NR), a precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+), has been extensively studied following oral administration, while the longer-term safety and physiological effects of injectable NR remain less characterized. Following an initial in-clinic phase evaluating repeat intramuscular (IM) and subcutaneous (SC) administration of pharmaceutical-grade NR, participants transitioned to an at-home phase designed to assess the safety, feasibility, and exploratory physiological effects of repeated self-administered SC administration. Participants continued their assigned 50 or 100 mg dose group and self-administered NR subcutaneously 3 times weekly for approximately 90 days. Safety was assessed through adverse event (AE) monitoring, vital signs, and clinical laboratory health measures. Exploratory assessments included markers of mitochondrial bioenergetics, urinary biomarkers of oxidative stress, and participant-reported outcomes related to fatigue, sleep, pain, and quality of life. At-home administration of NR was generally well-tolerated, with no clear dose-dependent safety concerns identified over the study period. Further, participants were able to successfully self-administer repeated SC injections over the study period, demonstrating positive feasibility. Whole-blood NAD+ concentrations remained largely stable over time in both dose groups. MeScreen analysis demonstrated a reduction in GlycoATP at Day 30 and increases in the MitoATP/GlycoATP ratio at Day 30 and Day 90, signifying a preferential shift toward oxidative metabolism. These findings may be indicative of positive metabolic health shifts. Urinary oxidative stress profiling demonstrated heterogeneous temporal responses. Several lipid oxidation markers significantly declined at Day 30 but returned toward baseline at Day 90. Select markers of nucleic acid, nitrative stress, and advanced glycation end-product oxidation demonstrated more sustained reductions. These results for which the majority of measured oxidative stress markers improved suggest that NR injections may exhibit anti-oxidative characteristics. Validated participant-reported sleep and fatigue measures showed improvements. Self-reported facial skin improvement increased descriptively from 11.4% at baseline to 27.8% at Day 30 and 36.8% at Day 90; improvements noticed by others increased from 9.1% to 23.7%, while reported body-skin improvement increased more modestly, from 8.8% to 16.7%. As these outcomes were not designed or powered to establish efficacy or definitive clinical claims, the findings should be considered hypothesis generating and provide preliminary data to inform the selection of outcomes and design considerations for future randomized, placebo-controlled, adequately powered trials of SC NR administration.

Significance Statement This is one of the first clinical trials evaluating safety and exploring the efficacy of nicotinamide riboside (NR) injections over an extended period. A favorable safety profile was observed for self-administered injections at doses of 50 and 100 mg. Quantitative changes in markers of mitochondrial efficiency and oxidative stress, and perceived self-reported improvements in functional outcomes of fatigue, sleep, and quality-of-life were independent of whole blood NAD+ measurements. This study is hypothesis generating and requires validation in future clinical trials.

Competing Interest Statement

YNE, JK, and AS were all employees of ChromaDex, Inc., a Niagen Bioscience, Inc. company, at the time this study was conducted and the manuscript was drafted. Niagen and Niagen Plus are proprietary ingredients of ChromaDex. AR, HC, TA, and Impact Health Medical were contracted by ChromaDex, Inc. to develop, conduct, and manage the study, including data analysis. AR, TA, and HC are also affiliated with Cell Theory, a multi-ingredient NAD+ support dietary supplement.

Clinical Trial

NCT07251608

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institute of Regenerative and Cellular Medicine Institutional Review Board - IRB00009500 - gave ethical approval for this work under Protocol number NB-2025-001 and Approval number IRCM-2025-451.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Funder Information Declared

ChromaDex (United States), https://ror.org/05xn6v862
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 15, 2026.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections
Anne Russ, Yasmeen Nkrumah-Elie, Frehiwet Hailu, Jun Kwon, Tracy Allen, Andrew Shao, Halland Chen
medRxiv 2026.10.13.26365470; doi: https://doi.org/10.64898/2026.10.13.26365470
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections
Anne Russ, Yasmeen Nkrumah-Elie, Frehiwet Hailu, Jun Kwon, Tracy Allen, Andrew Shao, Halland Chen
medRxiv 2026.10.13.26365470; doi: https://doi.org/10.64898/2026.10.13.26365470

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (638)
  • Allergy and Immunology (917)
  • Anesthesia (350)
  • Cardiovascular Medicine (4999)
  • Dentistry and Oral Medicine (494)
  • Dermatology (427)
  • Emergency Medicine (676)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1690)
  • Epidemiology (16253)
  • Forensic Medicine (36)
  • Gastroenterology (1241)
  • Genetic and Genomic Medicine (7274)
  • Geriatric Medicine (751)
  • Health Economics (1093)
  • Health Informatics (5283)
  • Health Policy (1467)
  • Health Systems and Quality Improvement (1832)
  • Hematology (599)
  • HIV/AIDS (1380)
  • Infectious Diseases (except HIV/AIDS) (16483)
  • Intensive Care and Critical Care Medicine (1203)
  • Medical Education (700)
  • Medical Ethics (156)
  • Nephrology (751)
  • Neurology (7586)
  • Nursing (377)
  • Nutrition (1127)
  • Obstetrics and Gynecology (1295)
  • Occupational and Environmental Health (1039)
  • Oncology (3742)
  • Ophthalmology (1092)
  • Orthopedics (408)
  • Otolaryngology (465)
  • Pain Medicine (501)
  • Palliative Medicine (143)
  • Pathology (721)
  • Pediatrics (1858)
  • Pharmacology and Therapeutics (755)
  • Primary Care Research (786)
  • Psychiatry and Clinical Psychology (6122)
  • Public and Global Health (9984)
  • Radiology and Imaging (2528)
  • Rehabilitation Medicine and Physical Therapy (1516)
  • Respiratory Medicine (1268)
  • Rheumatology (658)
  • Sexual and Reproductive Health (804)
  • Sports Medicine (595)
  • Surgery (802)
  • Toxicology (109)
  • Transplantation (318)
  • Urology (307)